PERK Inhibition by HC-5404 Sensitizes Renal Cell Carcinoma Tumor Models to Antiangiogenic Tyrosine Kinase Inhibitors

202324 citationsJournal Articlehybrid Open Access

Authors

Michael E. Stokes · FuelCell Energy (United States)

Verónica Calvo · Intellicell Biosciences (United States)

Sho Fujisawa · FuelCell Energy (United States)

Crissy Dudgeon · Intellicell Biosciences (United States)

Sharon Huang · Intellicell Biosciences (United States)

Nupur Ballal · Intellicell Biosciences (United States)

Leyi Shen

Abstract

By disrupting an adaptive stress response evoked by VEGFR-TKI, HC-5404 presents a clinical opportunity to improve the antitumor effects of well-established standard-of-care therapies in RCC.

Topics & Keywords

Renal cell carcinoma treatment Pancreatic and Hepatic Oncology Research Endoplasmic Reticulum Stress and Disease

Publication Details

Published in: Clinical Cancer Research

Volume 29, Issue 23, pp. 4870-4882

DOI: 10.1158/1078-0432.ccr-23-1182

Field-Weighted Citation Impact: 6.21

Command Palette

PERK Inhibition by HC-5404 Sensitizes Renal Cell Carcinoma Tumor Models to Antiangiogenic Tyrosine Kinase Inhibitors

Authors

Abstract

Topics & Keywords

Publication Details